{"id":578874,"date":"2021-12-13T18:16:02","date_gmt":"2021-12-13T18:16:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=578874"},"modified":"2021-12-13T18:16:02","modified_gmt":"2021-12-13T18:16:02","slug":"hypertriglyceridemia-pipeline-insights-2021-comprehensive-assessment-into-the-ongoing-clinical-trials-treatment-algorithm-novel-and-emerging-therapies","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/hypertriglyceridemia-pipeline-insights-2021-comprehensive-assessment-into-the-ongoing-clinical-trials-treatment-algorithm-novel-and-emerging-therapies_578874.html","title":{"rendered":"Hypertriglyceridemia Pipeline Insights, 2021: Comprehensive Assessment into the Ongoing Clinical Trials, Treatment Algorithm, Novel and Emerging Therapies"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Hypertriglyceridemia Pipeline Insights, 2021: Comprehensive Assessment into the Ongoing Clinical Trials, Treatment Algorithm, Novel and Emerging Therapies\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" alt=\"Hypertriglyceridemia Pipeline Insights, 2021: Comprehensive Assessment into the Ongoing Clinical Trials, Treatment Algorithm, Novel and Emerging Therapies\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s latest report on &#8220;Hypertriglyceridemia Pipeline Insight, 2021&#8221; outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hypertriglyceridemia Market.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">The <strong>Hypertriglyceridemia Pipeline report<\/strong> embraces in-depth commercial and clinical assessment of the Hypertriglyceridemia pipeline products from the pre-clinical developmental phase to the marketed phase.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report covers a detailed description of the drug including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hypertriglyceridemia collaborations, mergers, acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" title=\"Hypertriglyceridemia Pipeline Analysis\" src=\"https:\/\/www.abnewswire.com\/uploads\/b360704730418c2a58bec39addc0ccb6.jpg\" alt=\"Hypertriglyceridemia Pipeline Analysis\" \/><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/hypertriglyceridemia-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Hypertriglyceridemia Pipeline Analysis<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The report provides insights into:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report provides detailed insights about companies that are developing <strong>therapies for the treatment of Hypertriglyceridemia<\/strong> with aggregate therapies developed by each company for the same.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for the Hypertriglyceridemia Treatment.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Hypertriglyceridemia key companies<\/strong> involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Hypertriglyceridemia Drugs<\/strong> under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Hypertriglyceridemia market.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report is built using data and information traced from the researcher&#8217;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university websites and industry-specific third-party sources, etc.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/hypertriglyceridemia-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Hypertriglyceridemia Therapeutics Landscape<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>The dynamics of the Hypertriglyceridemia (HTG) market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world, and the expected launch of emerging therapies during the forecast period. <\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>Companies across the globe are thoroughly working towards the development of new treatment therapies for hypertriglyceridemia (HTG). The launch of the emerging therapies is expected to improve the treatment scenario in the coming years.<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Some of the key Companies in the Hypertriglyceridemia Market include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Regeneron Pharmaceuticals<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Acasti Pharma<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">AstraZeneca<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Amarin Pharma<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">GlaxoSmithKline<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Arrowhead Pharmaceuticals&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many others.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Hypertriglyceridemia Therapies covered in the report include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">CaPre<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">K-877<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Vascepa<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Evinacumab<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Epanova (omega-3-carboxylic acids)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Lovaza (omega-3-acid ethyl esters)<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many more.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Request for Sample Pages @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/hypertriglyceridemia-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">Hypertriglyceridemia Emerging Therapies and Key Companies&nbsp;<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Content<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Hypertriglyceridemia&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Hypertriglyceridemia Current Treatment Patterns<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Hypertriglyceridemia &#8211; DelveInsight&#8217;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Hypertriglyceridemia Late Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Hypertriglyceridemia Mid Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Inactive Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Dormant Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Hypertriglyceridemia Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Hypertriglyceridemia Product Profiles<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Hypertriglyceridemia Key Companies<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Hypertriglyceridemia Key Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">17. Hypertriglyceridemia Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">18. Hypertriglyceridemia Future Perspectives<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">19. Hypertriglyceridemia Analyst Review&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">20. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">21. Report Methodology<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>*The table of contents is not exhaustive; the final content may vary.&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Visit to get the sample report:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/hypertriglyceridemia-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/hypertriglyceridemia-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Latest Report by DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/malignant-pleural-mesothelioma-market\">Malignant Pleural Mesothelioma (MPM) Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight&#8217;s Malignant Pleural Mesothelioma (MPM) &#8211; Market Insights, Epidemiology and Market Forecast &#8211; 2030 report provides a detailed overview of the market size, share, trends, epidemiology, emerging therapies, and key companies in the domain.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56421.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=hypertriglyceridemia-pipeline-insights-2021-comprehensive-assessment-into-the-ongoing-clinical-trials-treatment-algorithm-novel-and-emerging-therapies\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 09650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=hypertriglyceridemia-pipeline-insights-2021-comprehensive-assessment-into-the-ongoing-clinical-trials-treatment-algorithm-novel-and-emerging-therapies\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delveinsight Business Research LLP DelveInsight&#8217;s latest report on &#8220;Hypertriglyceridemia Pipeline Insight, 2021&#8221; outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hypertriglyceridemia Market. The Hypertriglyceridemia Pipeline report embraces in-depth commercial and clinical assessment of the &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/hypertriglyceridemia-pipeline-insights-2021-comprehensive-assessment-into-the-ongoing-clinical-trials-treatment-algorithm-novel-and-emerging-therapies_578874.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[435,405,406,403,404],"tags":[],"class_list":["post-578874","post","type-post","status-publish","format-standard","hentry","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/578874","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=578874"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/578874\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=578874"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=578874"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=578874"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}